108 related articles for article (PubMed ID: 8938825)
1. No interaction between desipramine and bromperidol.
Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y
Prog Neuropsychopharmacol Biol Psychiatry; 1996 Oct; 20(7):1265-71. PubMed ID: 8938825
[TBL] [Abstract][Full Text] [Related]
2. Interaction between carbamazepine and bromperidol.
Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Furukori H; Kaneko S; Inoue Y
Eur J Clin Pharmacol; 1997; 52(3):219-22. PubMed ID: 9218929
[TBL] [Abstract][Full Text] [Related]
3. Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite.
Suzuki A; Otani K; Mihara K; Yasui N; Kondo T; Tokinaga N; Furukori H; Kaneko S; Inoue Y; Hayashi K
Psychopharmacology (Berl); 1998 Feb; 135(4):333-7. PubMed ID: 9539256
[TBL] [Abstract][Full Text] [Related]
4. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine.
Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y; Shibata M; Ikeda K
Ther Drug Monit; 1997 Jun; 19(3):261-4. PubMed ID: 9200764
[TBL] [Abstract][Full Text] [Related]
5. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
[TBL] [Abstract][Full Text] [Related]
6. No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol.
Mihara K; Otani K; Yasui N; Ishida M; Kondo T; Suzuki A; Furukori H; Nagashima U; Kaneko S; Inoue Y
Ther Drug Monit; 1999 Jun; 21(3):297-300. PubMed ID: 10365640
[TBL] [Abstract][Full Text] [Related]
7. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients.
Furukori H; Kondo T; Yasui N; Otani K; Tokinaga N; Nagashima U; Kaneko S; Inoue Y
Psychopharmacology (Berl); 1999 Jul; 145(2):189-92. PubMed ID: 10463320
[TBL] [Abstract][Full Text] [Related]
8. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
[TBL] [Abstract][Full Text] [Related]
9. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
Furukori H
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806
[TBL] [Abstract][Full Text] [Related]
10. Prolactin response to bromperidol treatment in schizophrenic patients.
Yasui N; Kondo T; Otani K; Ishida M; Mihara K; Suzuki A; Kaneko S; Inoue Y
Pharmacol Toxicol; 1998 Mar; 82(3):153-6. PubMed ID: 9553995
[TBL] [Abstract][Full Text] [Related]
11. Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay.
Yasui-Furukori N; Furukori H; Saito M; Inoue Y; Kaneko S; Tateishi T
Ther Drug Monit; 2003 Dec; 25(6):709-14. PubMed ID: 14639057
[TBL] [Abstract][Full Text] [Related]
12. No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite.
Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Kaneko S; Inoue Y; Shibata M; Ikeda K
Ther Drug Monit; 1997 Apr; 19(2):165-8. PubMed ID: 9108644
[TBL] [Abstract][Full Text] [Related]
13. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
[TBL] [Abstract][Full Text] [Related]
14. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):575-8. PubMed ID: 11999910
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography.
Yasui-Furukori N; Inoue Y; Chiba M; Tateishi T
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(1):175-80. PubMed ID: 15113555
[TBL] [Abstract][Full Text] [Related]
16. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes.
Tateishi T; Watanabe M; Kumai T; Tanaka M; Moriya H; Yamaguchi S; Satoh T; Kobayashi S
Life Sci; 2000 Nov; 67(24):2913-20. PubMed ID: 11133003
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.
Yasui-Furukori N; Kondo T; Ishida M; Furukori H; Suzuki A; Kaneko S; Inoue M; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):53-7. PubMed ID: 11853119
[TBL] [Abstract][Full Text] [Related]
18. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice.
Yasui N; Kondo T; Suzuki A; Otani K; Mihara K; Furukori H; Kaneko S; Inoue Y
Int Clin Psychopharmacol; 1999 Mar; 14(2):113-8. PubMed ID: 10220126
[TBL] [Abstract][Full Text] [Related]
19. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol.
Suzuki Y; Someya T; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Ther Drug Monit; 2001 Aug; 23(4):363-8. PubMed ID: 11477317
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic parameters of bromperidol in Korean subjects.
Lee SY; Kim YG; Kim HG; Kim JW
Hum Psychopharmacol; 2006 Aug; 21(6):409-12. PubMed ID: 16915578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
